Delivery of vaccines by nasal sprays may enable more robust, protective mucosal immune responses against infectious diseases, such as COVID-19, compared with intramuscular injection. In this Comment, we highlight how biomaterials can be designed to allow intranasal and inhaled vaccination.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Charge-assisted stabilization of lipid nanoparticles enables inhaled mRNA delivery for mucosal vaccination
Nature Communications Open Access 02 November 2024
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Topol, E. J. & Iwasaki, A. Operation nasal vaccine — lightning speed to counter COVID-19. Sci. Immunol. 74, Eadd9947 (2022).
Mao, T. et al. Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses. Science 378, eabo2523 (2022).
Hida, K. et al. Common gene therapy viral vectors do not efficiently penetrate sputum from cystic fibrosis patients. PloS One 6, e19919 (2011).
Kim, Y. C. et al. Strategy to enhance dendritic cell-mediated DNA vaccination in the lung. Adv. Ther. 4, 2000228 (2021).
Alameh, M.-G. et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity 54, 2877–2892 (2021).
Li, M. et al. Engineering intranasal MRNA vaccines to enhance lymph node trafficking and immune responses. Acta Biomater. 64, 237–48 (2017).
Wang, Z. et al. Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine. Nat. Biomed. Eng. 6, 791–805 (2022).
Si, Y., Wen, Y., Kelly, S. H., Chong, A. S. & Collier, J. H. Intranasal delivery of adjuvant-free peptide nanofibers elicits resident CD8+ T cell responses. J. Control. Release 282, 120–130 (2018).
Hartwell, B. L. et al. Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity. Sci. Transl Med. 14, eabn1413 (2022).
Zhuo, S.-H. et al. A chitosan-mediated inhalable nanovaccine against SARS-CoV-2. Nano. Res. 15, 4191–4200 (2022).
Acknowledgements
We acknowledge support from the National Institutes of Health (UMD-NCI Partnership for Integrative Cancer Research to D.C., R01HL160540 to G.A.D.) and the LAM Foundation (LAM Foundation Career Development Award to K.M.).
Author information
Authors and Affiliations
Contributions
All authors contributed to the conceptualization, drafting and editing of the manuscript.
Corresponding authors
Ethics declarations
Competing interests
All authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Cahn, D., Amosu, M., Maisel, K. et al. Biomaterials for intranasal and inhaled vaccine delivery. Nat Rev Bioeng 1, 83–84 (2023). https://doi.org/10.1038/s44222-022-00012-6
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s44222-022-00012-6
This article is cited by
-
Charge-assisted stabilization of lipid nanoparticles enables inhaled mRNA delivery for mucosal vaccination
Nature Communications (2024)
-
Nanomedicines via the pulmonary route: a promising strategy to reach the target?
Drug Delivery and Translational Research (2024)
-
A next-generation inhalable dry powder COVID vaccine
Nature (2023)
